MYRIAD GENETICS, INC. (MYGN) Total liabilities 2016–2025
MYRIAD GENETICS, INC. (MYGN) total liabilities at each fiscal year-end, per SEC filings.
$338.6MFY2025 · since FY2016: $440.9M → $338.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $338.6M | +3.7% |
| FY2024 | $326.5M | -10.1% |
| FY2023 | $363.3M | +16.1% |
| FY2022 | $312.9M | -11.3% |
| FY2021 | $352.9M | -34.4% |
| FY2020 | $537.8M | +10.6% |
| FY2019 | $486.4M | +2.7% |
| FY2018 | $473.8M | +126.5% |
| FY2017 | $209.2M | -52.6% |
| FY2016 | $440.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MYGN financial trends
MYGN RevenueMYGN Net incomeMYGN Net marginMYGN Gross profitMYGN Gross marginMYGN Operating incomeMYGN Operating marginMYGN Operating cash flowMYGN Free cash flowMYGN Capital expendituresMYGN Return on equityMYGN Stock buybacksMYGN Dividends paidMYGN Total assetsMYGN Shareholders’ equityMYGN overview →